Peter Young

Full-year business review of pharma and biotech sectors reveals strong momentum in advancing novel science and treatments, but likely foretells continued stock instability in near-to-medium terms.

Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.

Examining the key biopharma stock numbers and industry trends from a year that challenged the conduct of business and market stability like never before.

Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.

A review of market performance and trends in 2018 and first quarter of 2019 for the life sciences industry.

What the new rules mean for Chinese-related investments and acquisitions in the US.